MammaPrint effectively predicts chemotherapy benefit and distant recurrence-free interval in HR+HER2- early breast cancer. High-risk patients benefit significantly from chemotherapy, while low-risk ...
Breast cancer screening based on individual risk rather than annual screening is safe, effective and preferred by patients, ...
University of California, San Francisco investigators led WISDOM, a randomized comparison of risk-based breast cancer screening and annual mammography. Rates of stage ≥IIB breast cancers met a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback